Welcome to the Gene Scene! Each week, we will explore a gene from the ACMG Secondary Findings list—genes identified by the American College of Medical Genetics and Genomics as having clear, actionable health implications. These genes are included because they’re linked to serious but preventable or manageable conditions when identified early.…
Welcome to the Gene Scene! Each week, we will explore a gene from the ACMG Secondary Findings list—genes identified by the American College of Medical Genetics and Genomics as having clear, actionable health implications. These genes are included because they’re linked to serious but preventable or manageable conditions when identified early.…
Welcome to the Gene Scene! Each week, we will explore a gene from the ACMG Secondary Findings list—genes identified by the American College of Medical Genetics and Genomics as having clear, actionable health implications. These genes are included because they’re linked to serious but preventable or manageable conditions when identified early.…
I am excited to share results of our large case-control study of 488 people with sarcoma and 2,440 matched cancer-free controls. Our study published in the Journal of the National Cancer Institute (JNCI) sought to determine whether germline pathogenic variants (gPVs) were more frequent in people with sarcoma than in cancer-free controls…
Welcome to the Gene Scene! Each week, we will explore a gene from the ACMG Secondary Findings list—genes identified by the American College of Medical Genetics and Genomics as having clear, actionable health implications. These genes are included because they’re linked to serious but preventable or manageable conditions when identified early.…
Welcome to the Gene Scene! Each week, we will explore a gene from the ACMG Secondary Findings list—genes identified by the American College of Medical Genetics and Genomics as having clear, actionable health implications. These genes are included because they’re linked to serious but preventable or manageable conditions when identified early.…
As a research fellow in the Cancer Genetics and Prevention group at Dana-Farber Cancer Institute—trained as a medical oncologist in Spain and specializing in hereditary cancer and translational genomics—I am often asked how to counsel patients who carry rare pathogenic variants, particularly when evidence is limited or outdated. Few scenarios…
Dr. Melissa Frey, a gynecologic oncologist, cancer geneticist, and researcher based in New York City, uses digital tools to streamline family history intake, assess cancer and hereditary risk, and improve documentation. We’ve previously covered Dr. Frey’s work showing how digital history collection improved documentation and risk assessment…
Welcome to the Gene Scene! Each week, we will explore a gene from the ACMG Secondary Findings list—genes identified by the American College of Medical Genetics and Genomics as having clear, actionable health implications. These genes are included because they’re linked to serious but preventable or manageable conditions when identified early.…
Welcome to the Gene Scene! Each week, we will explore a gene from the ACMG Secondary Findings list—genes identified by the American College of Medical Genetics and Genomics as having clear, actionable health implications.These genes are included because they’re linked to serious but preventable or manageable conditions when identified early.…